Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes

  • Yan Li
  • Ning-Yuan Li
  • Edward M. Sellers


Comparison of 7-hydroxylation of coumarin, a CYP2A6 substrate, in human and African green and cynomolgus monkey liver microsomes was made by means of an HPLC assay with UV detection. In human liver microsomes, the Km and Vmax values for the metabolic conversion were 2.1 μM and 0.79 nmol/mg/min, respectively. While African green monkey showed Km and Vmax values of 2.7 μM and 0.52 nmol/mg/min, which were similar to human, higher Km and Vmax values were found in cynomolgus monkey. Coumarin 7-hydroxylation in human and African green monkey was selectively inhibited by methoxsalen and pilocarpine (CYP2A6 inhibitors) but not by other inhibitors, i.e. α-naphthoflavone (CYP1A1), orphenadrine (CYP2B6), sulfaphenazole (CYP2C9), quinidine (CYP2D6) and ketoconazole (CYP3A4). Immunoinhibition results supported CYP2A6 involvement in human and its homolog in monkey in coumarin 7-hydroxylation, as only anti-CYP2A6, but not CYP2B1, CYP2C13, CYP2D6, CYP2E1 or CYP3A antibodies, inhibited this conversion. African green monkey was found to be similar to human in catalytic activity of coumarin 7-hydroxylation and response to CYP2A6 inhibitors or antibody inhibition. However, the monkey CYP2A6 is not identical to the human in that Ki values were different, and differences were observed with some CYP2A6 inhibitors, such as nicotine and methoxsalen, suggesting that, under some circumstances, studies of nicotine kinetics and drug taking behavior in monkey may not be comparable to human.


CYP2A6 monkey human microsomes coumarin 7-hydroxylation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cashman J.R., Park S.B., Yang Z-C., Wrighton S.A., Jacob III P., Benowitz N.L. (1992): Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem. Res. Toxicol., 5, 639–646.CrossRefPubMedGoogle Scholar
  2. 2.
    McCracken N.W., Cholerton S., Idle J.R. (1992): Cotinine formation by cDNA-expressed human cytochrome P450. Med. Sci. Res., 20, 877–878.Google Scholar
  3. 3.
    Messina E.S., Tyndale R.F., Sellers E.M. (1997): A major role for CYP2A6 in nicotine C-oxidation by human liver microsome. J. Pharmacol. Exp. Ther., In press.Google Scholar
  4. 4.
    Fernandez-Salguero P., Gonzalez F.J. (1995): The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics, 5, S123-S128.CrossRefPubMedGoogle Scholar
  5. 5.
    Yamano S., Tatsuno J., Gonzalez F.J. (1990): The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 29, 1322–1329.CrossRefPubMedGoogle Scholar
  6. 6.
    Miles J.S., McLaren A.W., Forrester L.M., Glancey M.J., Lang M.A., Wolf C.R. (1990): Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem. J., 267, 365–371.PubMedGoogle Scholar
  7. 7.
    Yun C-H., Shimada T., Guengerich F.P. (1991): Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol., 40, 679–685.PubMedGoogle Scholar
  8. 8.
    Dalet-Beluche I., Boulenc X., Fabre G., Maurel P., Bonfils C. (1992): Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A heme families from monkey (baboon,Papio papio) liver microsomes. Cross reactivity with human forms. Eur. J. Biochem., 204, 641–648.CrossRefPubMedGoogle Scholar
  9. 9.
    Pearce R., Greenway D., Parkinson A. (1992): Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch. Biochem. Biophys., 298, 211–225.CrossRefPubMedGoogle Scholar
  10. 10.
    Pelkonen O., Sotaniemi E.A., Ahokas J.T. (1985): Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparisons. Br. J. Clin. Pharmacol., 19, 59–66.PubMedGoogle Scholar
  11. 11.
    Lake B.G., Gaudin H., Price R.J., Walters D.G. (1992): Metabolism of [3-14C] coumarin to polar and covalently bound products by hepatic microsomes from the rat, Syrian hamster, gerbil and humans. Fed. Chem. Toxicol., 30, 105–115.CrossRefGoogle Scholar
  12. 12.
    Stevens J.C., Shipley L.A., Cashman J.R., Vandenbranden M., Wrighton S.A. (1993): Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab. Dispos., 21, 753–760.PubMedGoogle Scholar
  13. 13.
    Steensma A., Beamand J.A., Walters D.G., Price R.J., Lake B.G. (1994): Metabolism of coumarin and 7-ethoxycoumarin by rat, mouse, guinea pig, cynomolgus monkey and human precision-cut liver slices. Xenobiotica, 24, 893–907.CrossRefPubMedGoogle Scholar
  14. 14.
    Sharer J.E., Shipley L.A., Vandenbranden M.R., Binkley S.N., Wrighton S.A. (1995): Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey and cynomolgus monkey. Drug Metab. Dispos., 23, 1231–1241.PubMedGoogle Scholar
  15. 15.
    Ohmori S. Horie T., Guengerich F.P., Kiuchi M., Kitada M. (1993): Purification and characterization of two forms of hepatic microsomal cytochrome P450 from untreated cynomolgus monkeys. Arch. Biochem. Biophys., 305, 405–413.CrossRefPubMedGoogle Scholar
  16. 16.
    Bourrie M., Meunier V., Berger Y., Fabre G. (1996): Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther., 277, 321–332.PubMedGoogle Scholar
  17. 17.
    Draper A.J., Madan A., Parkinson A. (1997): Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys., 341, 47–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Maenpaa J., Sigusch H., Raunio H. et al. (1993): Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem. Pharmacol., 45, 1035–1042.CrossRefPubMedGoogle Scholar
  19. 19.
    Chang T.K.H., Gonzalez F.J., Waxman D.J. (1994): Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys., 311, 437–442.CrossRefPubMedGoogle Scholar
  20. 20.
    Guengerich F.P. (1995). Human cytochrome P450 enzymes. In: Ortiz de Montellano, Paul R. (eds) Cytochrome P450: Structure, Mechanism, and Biochemistry. New York: Plenum, 473–535.Google Scholar
  21. 21.
    Lake B.G., Sauer M.J., Esclangon F., Beamand J.A., Price R.J., Walters D.G. (1995): Metabolism of coumarin by precision-cut calf liver slices and calf liver microsomes. Xenobiotica, 25, 133–141.CrossRefPubMedGoogle Scholar
  22. 22.
    Maenpaa J., Juvonen R., Raunio H., Rautio A., Pelkonen O. (1994): Metabolic interactions of methoxsalen and coumarin in humans and mice. 48, 1363–1369.Google Scholar
  23. 23.
    Raunio H., Syngelma T., Pasanen M. et al. (1988): Immunochemical and catalytic studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. Biochem. Pharmacol., 37, 3889–3895.CrossRefPubMedGoogle Scholar
  24. 24.
    Kimonen T., Juvonen R. O., Alhava E., Pasenen M. (1995): The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br. J. Pharmacol., 114, 832–836.PubMedGoogle Scholar
  25. 25.
    Nakajima M., Yamamoto T., Nunoya K-I. et al. (1996): Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther., 277, 1010–1015.PubMedGoogle Scholar
  26. 26.
    Nakajima M., Yamamoto T., Nunoya K-I. et al. (1996): Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos., 24, 1212–1217.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • Yan Li
    • 4
    • 1
    • 2
    • 3
  • Ning-Yuan Li
    • 4
    • 1
    • 2
    • 3
  • Edward M. Sellers
    • 4
    • 1
    • 2
    • 3
  1. 1.Department of Medicine and PsychiatryUniversity of TorontoTorontoCanada
  2. 2.Department of Psychopharmacology and Dependence Research Unit, Center for Research in Women’s HealthWomen’s College HospitalTorontoCanada
  3. 3.Addiction Research FoundationTorontoCanada
  4. 4.Department of Pharmacology, Room 4334, Medical Sciences BuildingUniversity of TorontoTorontoCanada

Personalised recommendations